Clinical trials: IDH1-mutant Glioma
Advanced Solid Tumor, IDH1 Mutation
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
In this study, response to treatment and (progression free and overall) survival will be described and safety events of ivosidenib in combination with nivolumab will be summarized in patients with advanced solid tumors…
- Conditions
- Advanced Solid Tumor, IDH1 Mutation, Glioma
- Trial name
- NCT04056910
- Testing
- ivosidenib and nivolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jason J. Luke, MD
Advanced Malignant Solid Neoplasm, Glioblastoma
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has spread from where it first started (primary site) to other places in…
- Conditions
- Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma
- Trial name
- NCT03212274
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 51 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)